PHAR

Pharming Group N.V. (NASDAQ:PHAR) is a Dutch biopharmaceutical company founded in 1988 and headquartered in Leiden, the Netherlands. The company went public on NASDAQ in December 2020 after previously trading on Euronext Amsterdam. Pharming specializes in developing and commercializing protein replacement therapies and precision medicines for rare diseases and unmet medical needs. The company has evolved from a research-focused biotechnology firm into a commercial-stage biopharmaceutical company with two marketed products and an expanding pipeline of treatments for rare genetic disorders.